Treating Hepatitis D With Bulevirtide – Real-World Experience From 114 Patients [PDF]
JHEP Reports, 2023 Background & Aims: Bulevirtide is a first-in-class entry inhibitor of hepatitis B surface antigen. In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most severe form of viral hepatitis, which frequently causes
Hartmut H-J Schmidt +2 more
exaly +5 more sources
Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy? [PDF]
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2020 Bulevirtide is a novel antiviral agent approved for suppression of chronic hepatitis D but requiring further research into optimising the treatment scheme.Aim.
V. E. Syutkin +2 more
doaj +4 more sources
Evaluation of the Drug-Drug Interaction Potential of the Novel Hepatitis B and D Virus Entry Inhibitor Bulevirtide at OATP1B in Healthy Volunteers [PDF]
Frontiers in Pharmacology, 2023 Introduction: Bulevirtide is a first-in-class antiviral drug to treat chronic hepatitis B/D. We investigated the drug-drug interaction potential and pharmacokinetics of high-dose subcutaneous bulevirtide (5 mg twice daily) with organic anion transporting
Vanessa Zhu +22 more
exaly +4 more sources
Effects of bulevirtide on atherosclerosis in an ApoE-deficient mouse model. [PDF]
PLoS ONEObjectiveBile acids are known to have a positive impact on atherosclerosis. The study investigates the impact of sodium taurocholate co-transporting polypeptide (NTCP) inhibition with bulevirtide, organic anion transporting polypeptide (OATP) inhibition ...
Jonas Rusnak +5 more
doaj +5 more sources
Treatment of Chronic Hepatitis D With Bulevirtide—A Fight Against Two Foes—An Update
Cells, 2022 HDV infection frequently causes progression to cirrhosis and hepatocellular carcinoma (HCC). In summer 2020, the first potentially effective drug Bulevirtide (BLV) has been approved for the treatment of HDV by the EMA.
Thomas Reiberger +2 more
exaly +4 more sources
Fate of hepatitis D virus-specific CD8+ T cells during bulevirtide monotherapy in patients with chronic hepatitis delta [PDF]
JHEP ReportsBackground & Aims: Bulevirtide reduces viremia in chronic hepatitis D virus (HDV) infection, but long-term treatment is required in most patients to prevent relapse.
Valerie Oberhardt +22 more
doaj +2 more sources
Clinical and Pathophysiological Considerations Related to the Impact of Bulevirtide, a New Entry Inhibitor, in HBV-HDV Infection [PDF]
VirusesThis review critically examines the inhibition of viral entry as an emerging disease-modifying strategy in chronic hepatitis B (HBV) and delta (HDV) virus infection, with particular emphasis on bulevirtide, the first-in-class of the sodium taurocholate ...
Raisa Eloise Barbu +9 more
doaj +2 more sources
JHEP Reports, 2023 Background & Aims: Bulevirtide (BLV) is a small lipopeptide agent that specifically binds to the sodium taurocholate cotransporting polypeptide (NTCP) bile salt transporter and HBV/HDV receptor on the surface of human hepatocytes and inhibits HDV and
Simin Xu +2 more
exaly +3 more sources
IL-37 and IL-36 Cytokine Profiles in Chronic Hepatitis Delta During Bulevirtide Therapy [PDF]
PathogensChronic hepatitis delta is the most severe form of viral hepatitis and is associated with rapid progression to cirrhosis and hepatocellular carcinoma. Although bulevirtide (BLV) effectively inhibits hepatitis D virus (HDV) entry, immunological biomarkers
Verdiana Zulian +6 more
doaj +2 more sources
Delta Describe, the French Collaborative Project: The Profile and Management of Hepatitis Delta Patients in Metropolitan France [PDF]
VirusesHepatitis delta (HDV) infection affects 5% of hepatitis B (HBV)-positive patients and is associated with an increased risk of cirrhosis and hepatocellular carcinoma; however, it remains underdiagnosed.
Marie Bosselut +33 more
doaj +2 more sources